SYRE vs. BBIO, CYTK, APLS, MDGL, ALPN, NUVL, ALKS, PRGO, CRNX, and AXSM
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include BridgeBio Pharma (BBIO), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical preparations" industry.
Spyre Therapeutics (NASDAQ:SYRE) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.
Spyre Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -246.24%.
Spyre Therapeutics has a beta of 2.93, indicating that its stock price is 193% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.
80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by company insiders. Comparatively, 24.7% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
BridgeBio Pharma received 133 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 68.25% of users gave BridgeBio Pharma an outperform vote.
Spyre Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
Spyre Therapeutics presently has a consensus price target of $43.17, indicating a potential upside of 23.51%. BridgeBio Pharma has a consensus price target of $47.62, indicating a potential upside of 69.99%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Spyre Therapeutics.
In the previous week, BridgeBio Pharma had 15 more articles in the media than Spyre Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 3 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.62 beat BridgeBio Pharma's score of 0.47 indicating that Spyre Therapeutics is being referred to more favorably in the media.
Summary
Spyre Therapeutics and BridgeBio Pharma tied by winning 9 of the 18 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
